slides · global inventory
Compare Peers
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 9,820
Current window 7,051-7,080
Pages 328
Rows per page 30
Slide function
7,051-7,080 of 9,820
21
The slide highlights specific safety data points for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
31
The slide uses a bubble chart to map clinical trial outcomes against patient treatment history and a table to detail specific drug performance metrics.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
46
The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo, likely to frame the market opportunity for IMX-120.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
09
Includes extensive disclaimer text regarding cross-trial comparison limitations.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
10
Includes detailed source citations in the footer.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
11
Includes detailed source citations in the footer; uses a color-coded legend for different drug treatments.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
20
The slide explicitly notes that these are cross-trial comparisons, not head-to-head studies.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
21
The slide uses a red dashed box to highlight the core clinical data rows for comparison.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
24
The slide highlights specific safety data points for a competitor product to establish a benchmark.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
49
The slide compares efficacy of Humira, Stelara, and Entyvio against placebo in clinical trials.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
05
The slide highlights NXC-201's superior efficacy (100% response rate) and safety profile (zero neurotoxicity) compared to existing therapies.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem1 hit
06
The slide explicitly notes that these are cross-trial comparisons and not head-to-head studies.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem1 hit
07
The slide uses a table structure to contrast standard of care with the company's target segment. The bottom section uses bar charts to imply relative patient population growth.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem1 hit
08
The slide explicitly warns about cross-trial comparison limitations in the footer.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem1 hit
20
The slide explicitly notes that these are cross-trial comparisons, not head-to-head studies.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
21
Includes detailed source citations and disclaimer regarding cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
22
The slide uses a comparison table framework to highlight NXC-201's competitive advantage in safety (lower ICANS/CRS) and efficacy (higher ORR/CR).Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
26
The slide highlights specific safety metrics for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
52
The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
05
The chart uses a 2x2 matrix structure to categorize peer performance based on volatility and returns.International General Insurance | Results Presentation Deck | 20 slides · International General Insurance
Conference presentation Investor relations Beat · WhyLoop · Benchmark Gap1 hit
11
The slide uses a bar chart to highlight JetBlue's position relative to competitors, with specific focus on liquidity and fuel hedging.jetBlue | Results Presentation Deck | 19 slides · jetBlue
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
30
The slide uses a comparison table to highlight superior efficacy metrics for the drug candidate.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
53
Includes a table comparing clinical stage and potency metrics (IC50, DC50) across multiple competitors.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
04
The slide uses a checkmark/cross matrix to demonstrate competitive advantage.Limbach Holdings | Investor Presentation Deck | 26 slides · Limbach
Pitch deck Investor relations Loop · Zoom In1 hit
05
The slide uses a 2x2 matrix to illustrate a strategic shift in business model positioning.Limbach Holdings | Investor Presentation Deck | 26 slides · Limbach
Pitch deck Investor relations Loop · Zoom In1 hit
10
The slide uses a timeline to show the evolution of the company's business model from 2017 to 2025.Limbach Holdings | Investor Presentation Deck | 26 slides · Limbach
Pitch deck Investor relations 1 hit
08
The slide uses a checkmark/cross matrix to demonstrate competitive differentiation.Limbach Holdings | Investor Presentation Deck | 27 slides · Limbach
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
09
The slide uses a 2x2 matrix to illustrate a strategic shift from a 'Specialty Contractor' profile to an 'Engineering/OEM' profile.Limbach Holdings | Investor Presentation Deck | 27 slides · Limbach
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
17
The chart highlights MAIN's cost efficiency by showing both its standard operating expense ratio and its ratio excluding non-cash compensation expenses.Main Street Capital | Fixed Income Presentation Deck | 42 slides · Main Street Capital Corporation
Conference presentation Investor relations 1 hit
37
The chart highlights MAIN's cost efficiency, specifically calling out non-cash compensation adjustments.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations Beat · Financials1 hit